|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 141.50 SAR | -1.67% |
|
+1.07% | -0.77% |
| Capitalization | 10.07B 2.69B 2.3B 2.15B 2B 3.73B 242B 4.02B 24.67B 9.71B 116B 9.87B 425B | P/E ratio 2025 * |
20.8x | P/E ratio 2026 * | 20.1x |
|---|---|---|---|---|---|
| Enterprise value | 9.85B 2.63B 2.25B 2.1B 1.95B 3.64B 237B 3.93B 24.12B 9.49B 113B 9.65B 416B | EV / Sales 2025 * |
6.64x | EV / Sales 2026 * | 5.74x |
| Free-Float |
30% | Yield 2025 * |
2.89% | Yield 2026 * | 3.12% |
Last Transcript: Jamjoom Pharmaceuticals Factory Company
| 1 day | -1.88% | ||
| 1 week | +1.07% | ||
| Current month | -0.77% | ||
| 1 month | -1.19% | ||
| 3 months | -12.84% | ||
| 6 months | -19.54% | ||
| Current year | -0.77% |
| 1 week | 139.7 |  | 145.9 |
| 1 month | 137 | | 145.9 |
| Current year | 137 | | 145.9 |
| 1 year | 134 | | 183.8 |
| 3 years | 66 | | 202.4 |
| 5 years | 66 | | 202.4 |
| 10 years | 66 | | 202.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tarek Hosni
CEO | Chief Executive Officer | 62 | 15/05/2021 |
Anwer Muhiddein
DFI | Director of Finance/CFO | 62 | 13/01/2013 |
Mohammed Jamjoom
COO | Chief Operating Officer | 31 | 01/09/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Faris Al Ghannam
BRD | Director/Board Member | - | 19/06/2022 |
| Chairman | 66 | 19/06/2022 | |
| Director/Board Member | 41 | 19/06/2022 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.67% | +1.07% | -11.31% | - | 2.69B | |
| -1.62% | -4.59% | -3.96% | +64.86% | 45.2B | |
| +3.44% | +0.99% | +59.21% | - | 33.03B | |
| +0.52% | +0.01% | +14.18% | +127.42% | 30.57B | |
| -0.95% | -2.28% | -0.92% | +34.35% | 12.84B | |
| -1.88% | -4.72% | -11.64% | +100.24% | 9.85B | |
| -4.46% | +1.77% | +71.17% | +44.62% | 8.36B | |
| +0.91% | +5.24% | +55.63% | +125.51% | 7.85B | |
| -.--% | +0.14% | - | - | 6.79B | |
| -0.28% | +1.24% | +39.80% | -20.86% | 6.78B | |
| Average | -0.62% | +0.04% | +23.57% | +68.02% | 16.4B | |
| Weighted average by Cap. | -0.07% | -0.77% | +21.35% | +77.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.48B 396M 340M 316M 294M 549M 35.72B 592M 3.63B 1.43B 17.09B 1.45B 62.61B | 1.7B 454M 390M 363M 338M 630M 41.02B 680M 4.17B 1.64B 19.62B 1.67B 71.91B |
| Net income | 485M 129M 111M 103M 96.15M 179M 11.67B 193M 1.19B 467M 5.58B 475M 20.46B | 502M 134M 115M 107M 99.57M 186M 12.09B 200M 1.23B 484M 5.78B 492M 21.19B |
| Net Debt | -224M -59.73M -51.25M -47.72M -44.41M -82.87M -5.39B -89.33M -549M -216M -2.58B -219M -9.45B | -298M -79.46M -68.18M -63.48M -59.08M -110M -7.17B -119M -730M -287M -3.43B -292M -12.57B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 141.50 ﷼ | -1.67% | 15,486 |
| 14/01/26 | 143.90 ﷼ | +0.28% | 68,509 |
| 13/01/26 | 143.50 ﷼ | +0.56% | 28,242 |
| 12/01/26 | 142.70 ﷼ | -0.21% | 31,258 |
| 11/01/26 | 143.00 ﷼ | +2.36% | 21,527 |
Delayed Quote Saudi Arabian S.E., January 15, 2026 at 10:35 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4015 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition